HIV drug resistance [5]

New England Journal of Medicine

Volumn 350, Issue 26, 2004, Pages 2720-2721

  Calmy, Alexandra ^a   Pascual, Fernando ^a   Ford, Nathan ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Doctors without Borders   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LOPINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

COST BENEFIT ANALYSIS; DRUG COST; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 2942729605     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200406243502621     Document Type: Letter

References (5)

1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004;350: 1023-35.
2. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63.
3. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Genera: World Health Organization, December 2003.
4. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 5th ed. Geneva: Médecins Sans Frontières, December 2003.
5. von Schoen Angerer T, Wilson D, Ford N, Kasper T. Access and activism: the ethics of providing antiretroviral therapy in developing countries. AIDS 2001;15:Suppl 5:S81-S90.